Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo‐controlled trial of darbepoetin alfa in patients with anemia and lower‐risk myelodysplastic syndromes. Leukemia. 2017; 31(9):1944–1950. doi:10.1038/leu.2017.192
71 71. Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo‐controlled study assessing the efficacy and safety of epoetin‐α in anemic patients with low‐risk MDS. Leukemia. 2018; 32(12):2648–2658. doi:10.1038/s41375‐018‐0118‐9
72 72. Hellström‐Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies. Br J Haematol. 1995; 89(1):67–71. doi:10.1111/j.1365‐2141.1995.tb08909.x
73 73. Hellström‐Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: Significant effects on quality of life. Br J Haematol. 2003; 120(6):1037–1046. doi:10.1046/j.1365‐2141.2003.04153.x
74 74. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‐CSF: The GFM experience. Blood. 2008; 111(2):574–582. doi:10.1182/blood‐2007‐06‐096370
75 75. J.R. W, Y.C. U, J.A. J, et al. Randomized, double‐blind, placebo‐controlled trial of erythropoietin in non‐small‐cell lung cancer with disease‐related anemia. J Clin Oncol. 2007; 25(9):1027–1032. doi:10.1200/JCO.2006.07.1514 LK ‐ http://WT3CF4ET2L.search.serialssolutions.com?sid=EMBASE&issn=0732183X&id=doi:10.1200%2FJCO.2006.07.1514&atitle=Randomized%2C+double‐blind%2C+placebo‐controlled+trial+of+erythropoietin+in+non‐small‐cell+lung+cancer+with+disease‐related+anemia&stitle=J.+Clin.+Oncol.&title=Journal+of+Clinical+Oncology&volume=25&issue=9&spage=1027&epage=1032&aulast=Wright&aufirst=James+R.&auinit=J.R.&aufull=Wright+J.R.&coden=JCOND&isbn=&pages=1027‐1032&date=2007&auinit1=J&auinitm=R
76 76. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study. J Clin Oncol. 2008; 26(7):1040–1050. doi:10.1200/JCO.2007.14.2885
77 77. Jädersten M, Montgomery SM, Dybedal I, Porwit‐MacDonald A, Hellström‐Lindberg E. Long‐term outcome of treatment of anemia in MDS with erythropoietin and G‐CSF. Blood. 2005; 106(3):803–811. doi:10.1182/blood‐2004‐10‐3872
78 78. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47–61. doi:10.1182/asheducation‐2001.1.47
79 79. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol. 2003; 509:91–125. doi:10.1007/978‐1‐4615‐0593‐8_6
80 80. Messa E, Cilloni D, Saglio G. Iron Chelation Therapy in Myelodysplastic Syndromes. Adv Hematol. 2010; 2010. doi:10.1155/2010/756289
81 81. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron‐overloaded patients with transfusion‐dependent myelodysplastic syndromes: Results from the large 1‐year EPIC study. Leuk Res. 2010; 34(9):1143–1150. doi:10.1016/j.leukres.2010.03.009
82 82. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83(11):858–861. doi:10.1002/ajh.21269
83 83. Suzuki T, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol. 2008; 88(1):30–35. doi:10.1007/s12185‐008‐0119‐y
84 84. Mittelman M, Lugassy G, Merkel D, et al. Iron chelation therapy in patients with myelodysplastic syndromes: Consensus conference guidelines. Isr Med Assoc J. 2008; 10(5):374–376.
85 85. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120(2):187–200. doi:10.1046/j.1365‐2141.2003.03907.x
86 86. Slichter SJ. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337(26):1861–1869. doi:10.1056/NEJM199712253372601
87 87. Syndromes ICSG for rHuEpo in M, Ferrini PR, Grossi A, et al. A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes. Br J Haematol. 1998; 103(4):1070–1074.
88 88. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion‐dependent patients with Low‐/Intermediate‐1‐risk myelodysplastic syndromes with del5q. Blood. 2011; 118(14):3765–3776. doi:10.1182/blood‐2011‐01‐330126
89 89. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion‐dependent patients with lower‐risk non‐del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis‐stimulating agents. J Clin Oncol. 2016; 34(25):2988–2996. doi:10.1200/JCO.2015.66.0118
90 90. Schiffer CA, Miller K, Larson RA, et al. A double‐blind, placebo‐controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000; 95(8):2530–2535. doi:10.1182/blood.v95.8.2530.008k31_2530_2535
91 91. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double‐blind, placebo‐controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG‐rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999; 94(11):3694–3701.
92 92. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low‐dose interleukin‐11 in patients with bone marrow failure. J Clin Oncol. 2001; 19(21):4165–4172. doi:10.1200/JCO.2001.19.21.4165
93 93. Kuter DJ, Bussel JB, Lyons RM, et al. Effi Cacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: A Double‐Blind Randomised Controlled Trial. Vol 371.; 2008.
94 94. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010; 28(3):437–444. doi:10.1200/JCO.2009.24.7999
95 95. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010; 116(17):3163–3170. doi:10.1182/blood‐2010‐03‐274753
96 96. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, non‐peptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739–4741. doi:10.1182/blood‐2006‐11‐057968
97 97. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 2002; 20(10):2429–2440. doi:10.1200/JCO.2002.04.117
98 98. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncol. 2009; 10(3):223–232. doi:10.1016/S1470‐2045(09)70003‐8
99 99. Lübbert M, Suciu S, Baila L, et al. Low‐dose decitabine versus best supportive care in elderly patients with intermediate‐ or high‐risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the european organisation for rese. J Clin Oncol. 2011; 29(15):1987–1996. doi:10.1200/JCO.2010.30.9245
100 100. Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016; 175(5):829–840. doi:10.1111/bjh.14305
101 101. Prébet T, Gore SD, Esterni B,